secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0001104659-25-022588
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax Chair James Young retires; Margaret McGlynn named successor; John Shiver joins board
--------------------------------------------------------------------------------

- James Young, PhD resigned as Board Chair effective March 10, 2025, after 15 years on the board.
- Margaret McGlynn, former Merck Vaccines president, appointed as Chair of the Board.
- John Shiver, PhD appointed as independent director; has 30+ years vaccine/RNA experience.
- Shiver receives initial equity grant of 35,770 options and 23,480 RSUs.
- No disagreement cited; changes part of planned board succession.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465925022588/0001104659-25-022588-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465925022588/tm258808d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-022588

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer